Anamorelin for Cancer Cachexia: A Ghrelin Agonist Against Wasting

The clinical problem

Cancer cachexia is a devastating wasting syndrome that affects many people with advanced cancer. It is more than simple weight loss: it involves progressive loss of skeletal muscle and lean body mass, often with reduced appetite (anorexia), and it worsens strength, quality of life, and tolerance of cancer treatment. Ordinary nutrition alone frequently cannot reverse it, because the underlying metabolism is disordered. There is a longstanding need for therapies that can help patients eat more and preserve muscle. This use case is educational and describes a clinician-managed area of oncology.

The rationale for a ghrelin agonist

The body's own appetite signal is ghrelin, the stomach hormone that acts on the GHSR-1a receptor to stimulate hunger and growth hormone release. In cachexia, this natural drive to eat is blunted. The therapeutic idea is straightforward: use a drug that mimics ghrelin to switch the appetite signal back on and support lean mass through the growth hormone axis.

Anamorelin is exactly that — an oral ghrelin/GHSR-1a receptor agonist. Being oral is a practical advantage for outpatients, and its mechanism connects directly to the appetite-regulation circuitry that cachexia disrupts. It targets the cachexia syndrome rather than the tumor itself.

What the evidence showed

Anamorelin was tested in a large clinical program (the ROMANA trials) in patients with advanced non-small-cell lung cancer. In these studies, anamorelin improved lean body mass and appetite compared with placebo — meeting its body-composition goals. However, it did not clearly improve measures of physical function, such as handgrip strength.

That gap proved decisive for regulators. Because a wasting therapy is ultimately meant to help patients feel and function better, and the functional benefit was not clearly demonstrated, the U.S. FDA declined to approve anamorelin. In the United States it is therefore not FDA-approved and remains investigational (research-only). It has, however, been approved in Japan (marketed as Adlumiz, from 2021) for cancer cachexia in certain cancers, including lung, gastrointestinal, and pancreatic cancer.

This split outcome is an honest reflection of a hard field: a drug can reliably do part of what is hoped — add muscle and appetite — without yet proving it changes what matters most to patients day to day.

Where it fits

Anamorelin is best understood as a targeted appetite-and-anabolism agent for cachexia, not a general nutritional supplement and not a cancer treatment. It does nothing to treat the underlying cancer, which is managed with standard oncology care. Where it is approved, it is used as part of a broader supportive-care approach that also includes nutrition, physical activity as tolerated, and management of symptoms that suppress appetite.

For readers comparing ghrelin-based drugs, it is worth noting the family shares a receptor but not a purpose: relamorelin targets gut motility rather than wasting, and macimorelin is a diagnostic for growth hormone deficiency. The common thread is the GHSR-1a receptor first defined by ghrelin.

The bottom line

Anamorelin illustrates both the promise and the limits of turning a natural hunger hormone into a medicine. It can improve appetite and lean mass in cancer cachexia, which is why it reached approval in Japan, but the absence of a clear functional benefit kept it from U.S. approval. Anyone encountering it should treat it as an investigational or regionally approved, clinician-managed therapy, not an established global standard of care.

This use case is educational and not medical advice. Anamorelin is not FDA-approved; where available it is a prescription medicine used under specialist supervision.